Nykode Therapeutics ASA (NYKD) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.15x

Nykode Therapeutics ASA (NYKD) has a Cash Flow Reinvestment Rate of 0.15x as of March 2022, reinvesting Nkr14.87 Million (capex Nkr14.06 Million plus investments Nkr817.00K) from operating cash flow of Nkr96.14 Million. See NYKD free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.15x

(Capex + Investments) / Operating CF

Total Reinvested

Nkr14.87 Million

Capex + Investments

Operating Cash Flow

Nkr96.14 Million

NOK

Capital Expenditures

Nkr14.06 Million

NOK

Nykode Therapeutics ASA Cash Flow Reinvestment Rate (2020–2021)

Historical reinvestment intensity for Nykode Therapeutics ASA across 2 annual periods. For the full cash flow conversion analysis, see Nykode Therapeutics ASA (NYKD) cash conversion ratio.

Annual Cash Flow Reinvestment Rate for Nykode Therapeutics ASA (2020–2021)

Year-by-year capital reinvestment analysis for Nykode Therapeutics ASA. See how financially flexible is Nykode Therapeutics ASA to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (NOK)	Operating CF	Capex	YoY Change
2021	10.58x	Nkr12.22 Million	Nkr1.16 Million	Nkr871.00K	▲ +31563.0%
2020	0.03x	Nkr6.03 Million	Nkr180.27 Million	Nkr99.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow